thalidomide has been researched along with mk-1775 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, W; Li, J; Liu, X; Shi, J; Zhang, Z; Zhao, L; Zhou, Y | 1 |
| Chung, M; Doctor, ZM; Donovan, KA; Eleuteri, NA; Fischer, ES; Gray, NS; Li, Z; Mills, CE; Nowak, RP; Olson, CM; Pinch, BJ; Scott, DA; Sorger, PK | 1 |
1 review(s) available for thalidomide and mk-1775
| Article | Year |
|---|---|
A review on the treatment of multiple myeloma with small molecular agents in the past five years.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Combined Modality Therapy; Deubiquitinating Enzymes; Drug Development; Drug Resistance; Histone Deacetylases; Humans; Ikaros Transcription Factor; Immunomodulating Agents; Models, Molecular; Morpholines; Multiple Myeloma; Phthalimides; Piperidones; Proteasome Inhibitors; Treatment Outcome; Ubiquitin-Protein Ligases | 2022 |
1 other study(ies) available for thalidomide and mk-1775
| Article | Year |
|---|---|
Development and Characterization of a Wee1 Kinase Degrader.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; DNA Damage; Drug Development; Female; Humans; Molecular Structure; Phthalazines; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteolysis; Pyrazoles; Pyrimidinones; Thalidomide | 2020 |